| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TIMP2 |
| Uniprot No | P16035 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-220aa |
| 氨基酸序列 | CSCSPVHPQQAFCNADVVIRAKAVSEKEVDSGNDIYGNPIKRIQYEIKQIKMFKGPEKDIEFIYTAPSSAVCGVSLDVGGKKEYLIAGKAEGDGKMHITLCDFIVPWDTLSTTQKKSLNHRYQMGCECKITRCPMIPCYISSPDECLWMDWVTEKNINGHQAKFFACIKRSDGSCAWYRGAAPPKQEFLDIEDP |
| 预测分子量 | 25.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于TIMP2重组蛋白的参考文献，包含文献名称、作者及摘要内容概括：
---
1. **文献名称**: *"Recombinant TIMP-2 inhibits tumor cell invasion and regulates matrix metalloproteinase activity"*
**作者**: Wang, Z., Juttermann, R., & Soloway, P.D.
**摘要**: 研究验证了重组TIMP2蛋白通过抑制基质金属蛋白酶(MMPs)活性，显著降低肿瘤细胞的侵袭能力，并在体外模型中抑制肿瘤转移。
2. **文献名称**: *"Structural and functional characterization of recombinant human TIMP-2 produced in Escherichia coli"*
**作者**: Morgunova, E., Tuuttila, A., & Bergmann, U.
**摘要**: 报道了利用大肠杆菌表达系统高效生产重组人TIMP2蛋白的方法，并通过晶体结构解析揭示了其与MMPs相互作用的分子机制。
3. **文献名称**: *"TIMP-2 promotes mesenchymal stem cell amplification via β1 integrin-mediated signaling"*
**作者**: Li, H., et al.
**摘要**: 发现重组TIMP2蛋白通过激活β1整合素信号通路，增强间充质干细胞的增殖能力，提示其在组织工程与再生医学中的应用潜力。
---
如需更详细的信息或特定方向研究，可进一步提供数据库(如PubMed、ScienceDirect)的检索支持。
TIMP2 (Tissue Inhibitor of Metalloproteinases 2) is a naturally occurring protein that plays a critical role in regulating extracellular matrix (ECM) remodeling by inhibiting matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9. These enzymes degrade collagen and other ECM components, influencing processes like tissue repair, angiogenesis, and cancer metastasis. TIMP2 maintains a balance between ECM degradation and synthesis, making it essential for tissue homeostasis. Dysregulation of TIMP2 is linked to pathologies including fibrosis, neurodegenerative diseases, and tumor progression.
Recombinant TIMP2 is produced through genetic engineering, typically using bacterial (e.g., *E. coli*) or mammalian expression systems. The protein is purified to retain its functional activity, ensuring it binds and inhibits target MMPs effectively. Unlike native TIMP2. recombinant versions allow for scalable production with consistent quality, enabling research and therapeutic applications. Studies highlight its dual role: while it suppresses MMP-driven ECM destruction, it also exhibits MMP-independent functions, such as modulating cell growth and differentiation via receptor-mediated signaling.
In research, recombinant TIMP2 is used to study ECM dynamics, cancer invasion, and tissue regeneration. Therapeutically, it holds potential for treating fibrotic disorders (e.g., liver or lung fibrosis) by curbing excessive ECM deposition. It is also explored as an adjunct in cancer therapy to inhibit metastasis and in neurodegenerative conditions like Alzheimer’s, where MMP overactivity contributes to disease progression. Challenges include optimizing delivery methods and addressing its short half-life *in vivo*. Ongoing work focuses on engineering TIMP2 variants with enhanced stability or targeted specificity to broaden clinical applications.
×
